2023
Ondruššek, Róbert; Kvokačková, Barbora; Kryštofová, Karolína; Brychtová, Světlana; Souček, Karel; Bouchal, Jan
Prognostic value and multifaceted roles of tetraspanin CD9 in cancer. Journal Article
In: Frontiers in oncology, vol. 13, pp. 1140738, 2023, ISSN: 2234-943X, (Place: Switzerland).
Abstract | Links | BibTeX | Tags: cancer, CD9, exosomes, Immunohistochemistry, Prognosis
@article{ondrussek_prognostic_2023,
title = {Prognostic value and multifaceted roles of tetraspanin CD9 in cancer.},
author = {Róbert Ondruššek and Barbora Kvokačková and Karolína Kryštofová and Světlana Brychtová and Karel Souček and Jan Bouchal},
doi = {10.3389/fonc.2023.1140738},
issn = {2234-943X},
year = {2023},
date = {2023-01-01},
journal = {Frontiers in oncology},
volume = {13},
pages = {1140738},
abstract = {CD9 is a crucial regulator of cell adhesion in the immune system and plays important physiological roles in hematopoiesis, blood coagulation or viral and bacterial infections. It is involved in the transendothelial migration of leukocytes which might also be hijacked by cancer cells during their invasion and metastasis. CD9 is found at the cell surface and the membrane of exosomes affecting cancer progression and therapy resistance. High expression of CD9 is mostly associated with good patients outcome, with a few exceptions. Discordant findings have been reported for breast, ovarian, melanoma, pancreatic and esophageal cancer, which might be related to using different antibodies or inherent cancer heterogeneity. According to in vitro and in vivo studies, tetraspanin CD9 is not clearly associated with either tumor suppression or promotion. Further mechanistic experiments will elucidate the role of CD9 in particular cancer types and specific conditions.},
note = {Place: Switzerland},
keywords = {cancer, CD9, exosomes, Immunohistochemistry, Prognosis},
pubstate = {published},
tppubtype = {article}
}
CD9 is a crucial regulator of cell adhesion in the immune system and plays important physiological roles in hematopoiesis, blood coagulation or viral and bacterial infections. It is involved in the transendothelial migration of leukocytes which might also be hijacked by cancer cells during their invasion and metastasis. CD9 is found at the cell surface and the membrane of exosomes affecting cancer progression and therapy resistance. High expression of CD9 is mostly associated with good patients outcome, with a few exceptions. Discordant findings have been reported for breast, ovarian, melanoma, pancreatic and esophageal cancer, which might be related to using different antibodies or inherent cancer heterogeneity. According to in vitro and in vivo studies, tetraspanin CD9 is not clearly associated with either tumor suppression or promotion. Further mechanistic experiments will elucidate the role of CD9 in particular cancer types and specific conditions.
2020
Lenárt, Sára; Lenárt, Peter; Šmarda, Jan; Remšík, Ján; Souček, Karel; Beneš, Petr
Trop2: Jack of All Trades, Master of None. Journal Article
In: Cancers, vol. 12, no. 11, 2020, ISSN: 2072-6694, (Place: Switzerland).
Abstract | Links | BibTeX | Tags: cancer, epithelial-to-mesenchymal transition, metastases, proliferation, TACSTD2, therapy, Trop2
@article{lenart_trop2_2020,
title = {Trop2: Jack of All Trades, Master of None.},
author = {Sára Lenárt and Peter Lenárt and Jan Šmarda and Ján Remšík and Karel Souček and Petr Beneš},
doi = {10.3390/cancers12113328},
issn = {2072-6694},
year = {2020},
date = {2020-11-01},
journal = {Cancers},
volume = {12},
number = {11},
abstract = {Trophoblast cell surface antigen 2 (Trop2) is a widely expressed glycoprotein and an epithelial cell adhesion molecule (EpCAM) family member. Although initially identified as a transmembrane protein, other subcellular localizations and processed forms were described. Its congenital mutations cause a gelatinous drop-like corneal dystrophy, a disease characterized by loss of barrier function in corneal epithelial cells. Trop2 is considered a stem cell marker and its expression associates with regenerative capacity in various tissues. Trop2 overexpression was described in tumors of different origins; however, functional studies revealed both oncogenic and tumor suppressor roles. Nevertheless, therapeutic potential of Trop2 was recognized and clinical studies with drug-antibody conjugates have been initiated in various cancer types. One of these agents, sacituzumab govitecan, has been recently granted an accelerated approval for therapy of metastatic triple-negative breast cancer. In this article, we review the current knowledge about the yet controversial function of Trop2 in homeostasis and pathology.},
note = {Place: Switzerland},
keywords = {cancer, epithelial-to-mesenchymal transition, metastases, proliferation, TACSTD2, therapy, Trop2},
pubstate = {published},
tppubtype = {article}
}
Trophoblast cell surface antigen 2 (Trop2) is a widely expressed glycoprotein and an epithelial cell adhesion molecule (EpCAM) family member. Although initially identified as a transmembrane protein, other subcellular localizations and processed forms were described. Its congenital mutations cause a gelatinous drop-like corneal dystrophy, a disease characterized by loss of barrier function in corneal epithelial cells. Trop2 is considered a stem cell marker and its expression associates with regenerative capacity in various tissues. Trop2 overexpression was described in tumors of different origins; however, functional studies revealed both oncogenic and tumor suppressor roles. Nevertheless, therapeutic potential of Trop2 was recognized and clinical studies with drug-antibody conjugates have been initiated in various cancer types. One of these agents, sacituzumab govitecan, has been recently granted an accelerated approval for therapy of metastatic triple-negative breast cancer. In this article, we review the current knowledge about the yet controversial function of Trop2 in homeostasis and pathology.